Evidence map›Paper›PMID 41414679›Full record

ArticleRenal failure2025

Fedratinib in chronic kidney disease: antifibrotic potential and renal safety signals from integrated network toxicology and pharmacovigilance.

Rubin Zheng, Jiaxi Chen, Qin Wang, Jiayi Lyu, Miao Deng, Jinfen Han, Haiou Wang, Zhixun Bai

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rubin ZhengDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Jiaxi ChenDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Qin WangDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Jiayi LyuDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Miao DengDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Jinfen HanDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Haiou WangDepartment of Pharmacy, People's Hospital of Qianxinan Prefecture, Xingyi, China.
Zhixun BaiDepartment of Nephrology, People's Hospital of Qianxinan Prefecture, Xingyi, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic kidney disease (CKD), a major global health challenge driven by renal fibrosis, lacks effective antifibrotic therapies. Fedratinib, a JAK2 inhibitor for myelofibrosis, shows kinase-modulating potential but uncharacterized utility and safety in CKD. Computational toxicity prediction utilized ProTox3.0 and ADMETlab2.0. Fedratinib-CKD targets were identified

Indexed as

Protein Kinase InhibitorsPyrrolidinesRenal Insufficiency, ChronicAdverse Drug Reaction Reporting SystemsBenzenesulfonamidesFibrosisHumansJanus Kinase 2KidneyMolecular Docking SimulationNetwork PharmacologyPharmacovigilanceProtein Interaction MapsBenzenesulfonamidesfedratinibJAK2 protein, humanJanus Kinase 2Protein Kinase InhibitorsPyrrolidinesChronic kidney disease (CKD)FedratinibJAK2 inhibitorMolecular dockingNetwork pharmacologyPharmacovigilance (FAERS)

Identifiers

PMID41414679
PMCPMC12720699

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.